Altered leucocyte chemotaxis function in HIV subjects

Nuhu Andrew Yashim
2013 Journal of Blood Disorders & Transfusion  
G lycoprotein IIb/IIIa inhibitors are important in the treatment of acute coronary syndromes (ACS) and percutaneous coronary interventions due to their effects on the final common pathway of platelet aggregation. Z4A5 is a new hexapeptide IIb/IIIa inhibitor with antiplatelet and antithrombotic effects. This study was performed to assess the stability of the antiplatelet effects and characteristics of Z4A5 with long-term infusion. Light-transmission aggregometry was used to measure platelet
more » ... asure platelet aggregation to assess the antiplatelet efficacy of Z4A5 in vitro and ex vivo. The activity of Z4A5 against platelet aggregation and template bleeding time were evaluated after 8-hour intravenous infusions in Beagle dogs following a 3×3 Latin square design. The recovery of platelet function after suppression by Z4A5 was compared with the recovery following eptifibatide and tirofiban administration 4h after termination. Z4A5 completely inhibited Adenosine diphosphate (ADP)-induced in vitro platelet aggregation with an IC50 of 265.8±22.9 nM. It also markedly and stably prevented ADP-induced ex vivo platelet aggregation and prolonged the bleeding time throughout the 8-hour infusion. Platelet function suppressed by long-term infusion of Z4A5 recovered significantly faster than after eptifibatide infusion. Consistent with the faster platelet function recovery, the template bleeding time returned to baseline sooner after Z4A5 infusion. Z4A5 can be more readily controlled by physicians to monitor platelet function and is safer for clinical use because it decreases the risk of post-dose bleeding in ACS patients compared with two other GP IIb/IIIa inhibitors. Xiao-Lian Shi, J Blood Disord Transfus 2013, 4:5 http://dx.
doi:10.4172/2155-9864.s1.003 fatcat:kpvkojbdzbepfgk5lo3wf6vflu